Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.83 USD
-0.22 (-10.54%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.85 +0.03 (1.37%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
PACB 1.83 -0.22(-10.54%)
Will PACB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PACB
Pacific Biosciences of California (PACB) Surpasses Market Returns: Some Facts Worth Knowing
PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PacBio's Stock Up on Munster Deal for Male Infertility Research
Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
Other News for PACB
PacBio Announces the HiFi Solves Sub-fertility Consortium in Asia Pacific
PacBio announces the HiFi Solves Sub-fertility Consortium
BIOSECURE Act passage would be modest positive for Illumina, says Canaccord
Commit To Purchase Pacific Biosciences of California At $1, Earn 43.5% Annualized Using Options
Revio to Power Research in Male Infertility and Rare Disease at Munster University Hospital